Anders Weilandt - Chordate Medical CEO MD
| CMH Stock | 8.82 0.30 3.29% |
Insider
Anders Weilandt is CEO MD of Chordate Medical Holding
| Age | 62 |
| Phone | 46 8 40 01 15 86 |
| Web | https://www.chordate.com |
Chordate Medical Management Efficiency
The company has return on total asset (ROA) of (0.7129) % which means that it has lost $0.7129 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.6754) %, meaning that it generated substantial loss on money invested by shareholders. Chordate Medical's management efficiency ratios could be used to measure how well Chordate Medical manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Pal Ryfors | Episurf Medical AB | 40 | |
| Marie MSc | Clinical Laserthermia Systems | 44 | |
| Mats Ekelund | Clinical Laserthermia Systems | N/A | |
| Fredrik Zetterberg | Episurf Medical AB | 48 | |
| Stephen Caswell | Episurf Medical AB | 42 | |
| Dan Mogren | Clinical Laserthermia Systems | N/A | |
| Veronica Wallin | Episurf Medical AB | 37 | |
| Stephan MSc | Clinical Laserthermia Systems | 68 | |
| Rolf Bornschein | Clinical Laserthermia Systems | N/A | |
| Beata Lihammar | Episurf Medical AB | N/A | |
| Patrick Jamnik | Episurf Medical AB | 40 | |
| Michael Nsstrm | Episurf Medical AB | 34 | |
| LarsErik Eriksson | Clinical Laserthermia Systems | 74 | |
| Katarina Flodstrm | Episurf Medical AB | 48 | |
| Karin Peterson | Clinical Laserthermia Systems | N/A | |
Management Performance
| Return On Equity | -1.68 | |||
| Return On Asset | -0.71 |
Chordate Medical Holding Leadership Team
Elected by the shareholders, the Chordate Medical's board of directors comprises two types of representatives: Chordate Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Chordate. The board's role is to monitor Chordate Medical's management team and ensure that shareholders' interests are well served. Chordate Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Chordate Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jan Hermansson, Head Director | ||
| Anders Weilandt, CEO MD | ||
| Jan Lindberg, CTO Mang | ||
| Niklas Lindecrantz, Chief Officer | ||
| Helena Thedius, Sales Mang |
Chordate Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Chordate Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.68 | |||
| Return On Asset | -0.71 | |||
| Operating Margin | (54.40) % | |||
| Current Valuation | 102.78 M | |||
| Shares Outstanding | 157.71 M | |||
| Shares Owned By Insiders | 39.97 % | |||
| Price To Book | 5.80 X | |||
| Price To Sales | 3,320 X | |||
| Revenue | 618.01 K | |||
| Gross Profit | 1.93 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Chordate Stock Analysis
When running Chordate Medical's price analysis, check to measure Chordate Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Chordate Medical is operating at the current time. Most of Chordate Medical's value examination focuses on studying past and present price action to predict the probability of Chordate Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Chordate Medical's price. Additionally, you may evaluate how the addition of Chordate Medical to your portfolios can decrease your overall portfolio volatility.